Clarivate Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Acute myeloid leukemia patient populations covering 171 countries…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key chronic myeloid leukemia patient populations covering 171 countries…
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, AML treatment has been dominated by…
Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stemcell disorders that result in cytopenias and the risk of progression to acute myeloid leukemia (AML). Although…
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, AML treatment has been dominated by…
Acute myeloid leukemia (AML) is the most common and aggressive form of leukemia in adults, with the lowest survival rates of all blood cancer types. Despite significant advances in understanding…
MARKET OUTLOOK Acute myeloid leukemia (AML) is the most common and aggressive form of leukemia in adults, with the lowest survival rates of all blood cancer types. Despite significant advances in…
Myelodysplastic syndromes ( MDS ) is a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and risk of progression to acute myeloid leukemia ( AML ). Management…
Chronic myeloid leukemia is a slow progressive tumor, characterized by different phases of disease (chronic, accelerated, and blast). Treatment of chronic myeloid leukemia is dominated by oral BCR-…
Acute myeloid leukemia is the most common form of acute leukemia in adults. Its incidence in the major pharmaceutical markets under study is increasing, largely as a result of the aging population…
The chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML) markets are becoming increasingly crowded, with recent marketing authorizations expanding therapy options for patients. As…
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis…
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis…
Myelodysplastic syndromes ( MDS ) is a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and risk of progression to acute myeloid leukemia ( AML ). Management…